Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Goldman Sachs Lifts AstraZeneca Target as Stock Rises

Guavy AI Editorial Team
Instruments
GS
Share

AstraZeneca stock has seen a significant gain following Goldman Sachs' decision to raise its target price for the pharmaceutical company.

The investment bank increased its target from 16,300 pence to 16,526 pence, representing an increase of 226 pence or approximately 1.4 percent.

This move comes after AstraZeneca's Chief Executive, Pascal Soriot, purchased 60,000 shares at a price of 121.02 GBP on September 14, 2026, providing further support for the stock.

The company's recent Q2 2026 earnings report showed revenue increasing by 5.84 percent year-over-year to 11.46 billion GBP, with earnings per share rising to 1.20 GBP in the same period.

More on Stocks

Stocks 2m ago

AI-Powered Stocks Gain Traction Amid Industry Boom

Stocks 5m ago

Exxon Mobil Takes the Crown as More Durable Dividend Payor

Stocks 5m ago

Coca-Cola Invests $10 Billion in U.S. Infrastructure Amid White House Claims

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy